Satralizumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neuromyelitis Optica Spectrum Disorder
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD
Trial Timeline
Mar 31, 2026 → Sep 12, 2029
NCT ID
NCT05199688About Satralizumab
Satralizumab is a phase 3 stage product being developed by Roche for Neuromyelitis Optica Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05199688. Target conditions include Neuromyelitis Optica Spectrum Disorder, NMOSD.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05199688 | Phase 3 | Recruiting |
| NCT06450639 | Phase 2 | Recruiting |
Competing Products
8 competing products in Neuromyelitis Optica Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |